ELI LILLY & Co — Form SCHEDULE 13D
Filed October 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 24/100
What the filing says
Eli Lilly & Co filed a Schedule 13D on October 16, 2026, indicating acquisition of beneficial ownership in TRex Bio, Inc., a Delaware-incorporated biological products company based in South San Francisco. The filing itself does not specify the dollar amount, percentage ownership stake, share count, or detailed terms of the transaction in the metadata provided; Schedule 13D typically requires these details in the full document text, which is not presented here.
Why this rating
Schedule 13D filing is routine disclosure; specifics (price, % stake) unknown from metadata. Eli Lilly's $807.9B scale makes typical biotech acquisitions modest relative to enterprise value.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.